Literature DB >> 30745146

Analysis of relative effectiveness of high-dose versus standard-dose influenza vaccines using an instrumental variable method.

Yinong Young-Xu1, Julia Thornton Snider2, Robertus van Aalst3, Salaheddin M Mahmud4, Edward W Thommes5, Jason K H Lee6, David P Greenberg7, Ayman Chit8.   

Abstract

BACKGROUND: Observational studies of the relative effectiveness of influenza vaccines are essential for public health decision making. Their estimates, however, are subject to bias due to unmeasured confounders. Instrumental variable (IV) methods can control for observed and unobserved confounders.
METHODS: We used linked electronic medical record databases in the Veterans Health Administration (VHA) as well as Medicare administrative files to examine the relative vaccine effectiveness (rVE) of high-dose influenza vaccine (HD) versus standard-dose influenza vaccines (SD) in preventing hospitalizations among VHA-enrolled Veterans ≥65 years of age during 5 influenza seasons (2010-2011 through 2014-2015). Using multivariable IV Poisson regression modeling to address unmeasured confounding and bias, we analyzed the data by each season and through longitudinal analysis of all five seasons.
FINDINGS: We included 3,638,924 person-influenza seasons of observation where 158,636 (4%) were among HD vaccine recipients and 3,480,288 (96%) were among SD vaccine recipients. Of the 1,728,562 Veterans, 1,702,824 (98.5%) were male and 1,299,412 (75%) were non-Hispanic white. Based on the longitudinal analysis of all five seasons, the IV-adjusted rVE estimate of HD vs. SD was 10% (95% CI, 8-12%) against all-cause hospitalization; 18% (95% CI, 15-21%) against cardiorespiratory-associated hospitalization; and 14% (95% CI, 6-22%) against influenza/pneumonia-associated hospitalization. The findings by season were similar.
INTERPRETATION: Our analysis of VHA clinical data collected from approximately 1.7 million Veterans 65 years and older during five seasons demonstrates that high-dose influenza vaccine is more effective than standard-dose influenza vaccines in preventing influenza- or pneumonia-associated hospitalizations, cardiorespiratory hospitalizations, and all-cause hospitalizations. Published by Elsevier Ltd.

Entities:  

Keywords:  High-dose vaccine; Influenza; Instrumental variable

Year:  2019        PMID: 30745146     DOI: 10.1016/j.vaccine.2019.01.063

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial.

Authors:  Leilani Sanchez; Osamu Matsuoka; Satoshi Inoue; Takahiro Inoue; Ya Meng; Takahiro Nakama; Kumiko Kato; Aseem Pandey; Lee-Jah Chang
Journal:  Hum Vaccin Immunother       Date:  2019-11-19       Impact factor: 3.452

2.  A Real-World Clinical and Economic Analysis of Cell-Derived Quadrivalent Influenza Vaccine Compared to Standard Egg-Derived Quadrivalent Influenza Vaccines During the 2019-2020 Influenza Season in the United States.

Authors:  Victoria Divino; Vamshi Ruthwik Anupindi; Mitch DeKoven; Joaquin Mould-Quevedo; Stephen I Pelton; Maarten J Postma; Myron J Levin
Journal:  Open Forum Infect Dis       Date:  2021-12-04       Impact factor: 3.835

3.  The feasibility of pragmatic influenza vaccine randomized controlled real-world trials in Denmark and England.

Authors:  Joshua Nealon; Daniel Modin; Rebecca E Ghosh; Deborah Rudin; Gunnar Gislason; Helen P Booth; Jens Ulrik Stæhr Jensen; Rachael Williams; Hilary Shepherd; Eleanor Yelland; Helene Bricout; Sandra S Chaves; Tor Biering-Sørensen
Journal:  NPJ Vaccines       Date:  2022-02-23       Impact factor: 7.344

4.  Estimation of Relative Vaccine Effectiveness in Influenza: A Systematic Review of Methodology.

Authors:  Martina E McMenamin; Helen S Bond; Sheena G Sullivan; Benjamin J Cowling
Journal:  Epidemiology       Date:  2022-05-01       Impact factor: 4.822

5.  Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 Influenza Season.

Authors:  Lisa A Grohskopf; Lenee H Blanton; Jill M Ferdinands; Jessie R Chung; Karen R Broder; H Keipp Talbot; Rebecca L Morgan; Alicia M Fry
Journal:  MMWR Recomm Rep       Date:  2022-08-26

6.  High-dose influenza vaccination and mortality among predominantly male, white, senior veterans, United States, 2012/13 to 2014/15.

Authors:  Yinong Young-Xu; Julia Thornton Snider; Salaheddin M Mahmud; Ellyn M Russo; Robertus Van Aalst; Edward W Thommes; Jason Kh Lee; Ayman Chit
Journal:  Euro Surveill       Date:  2020-05

Review 7.  [High-dose trivalent influenza vaccine. Efficacy and effectiveness].

Authors:  A Gil de Miguel; E Redondo Marguello; J Díez Domingo; R Ortiz de Lejarazu; F Martinón Torres
Journal:  Rev Esp Quimioter       Date:  2020-06-09       Impact factor: 1.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.